Edgewise completes sale of sevasemten to Servier for $2.65 billion.
Edgewise finalized the sale of its muscular dystrophy business to Servier for $1.55 billion upfront. The transaction provides financial flexibility to advance its cardiovascular pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day